We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Vascular Endothelial Growth Factor Levels at Hysteroscopic Biopsies Which Taken From Recurrent Pregnancy Loss

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01735331
Recruitment Status : Completed
First Posted : November 28, 2012
Last Update Posted : August 7, 2015
Sponsor:
Information provided by (Responsible Party):
Bagcilar Training and Research Hospital

Brief Summary:
The aim of this study is determine vascular endothelial growth factor levels and angiogenesis/vascularity from hysteroscopic endometrial biopsies which taken from patients who has Recurrent Pregnancy Loss.The endometrial vascular endothelial growth factor levels will be measured by immunohistochemical staining methods due to office hysteroscopic endometrial biopsy after the menstruation at follicular phase of menstrual cycle.

Condition or disease
Recurrent Pregnancy Loss Without Current Pregnancy

Detailed Description:

This study is a prospective,observational,single-center study.Ethical approval was obtained from the Institutional Review Board.This study will be completed 30 patients with Habitual Abortus.

Endometrial vascular endothelial growth factor levels will be measured using Flk-1 / Kinase Domain Receptor / Vascular endothelial growth factor receptor-2, Ab-1 (Rabbit PAb), Vascular Endothelial Growth Factor (VEGF) Ab-7 (VG1), Cluster of Differentiation 34 (Endothelial Cell Marker) Ab-1 (QBEnd/10), Vascular endothelial growth factor receptor-1 (N-term) (FLT1) antibody kits. All assays will be performed according to the manufacturer's instructions.


Study Type : Observational
Actual Enrollment : 30 participants
Observational Model: Case Control
Time Perspective: Prospective
Official Title: Vascular Endothelial Growth Factor Levels at Hysteroscopic Biopsies Which Taken From Recurrent Pregnancy Loss
Study Start Date : November 2012
Primary Completion Date : August 2013
Study Completion Date : August 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Biopsy
U.S. FDA Resources

Group/Cohort
VEGF level
VEGF level in hysteroscopic endometrial biopsy of the patients with recurrent pregnancy loss.
control group
Patients with Abnormal Uterine Bleeding



Primary Outcome Measures :
  1. The primary outcome measure of this study is to determine endometrial vascular endothelial growth factor levels in patient with Recurrent Pregnancy Loss [ Time Frame: 3 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
The patients with Recurrent Pregnancy Loss
Criteria

Inclusion Criteria:

  • Patients with Recurrent Pregnancy Loss who accept to join the study.

Exclusion Criteria:

  • Patients whose age of <18 and >45
  • Patients with have any pregnancy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01735331


Locations
Turkey
Bagcilar Training and Research Hospital
Istanbul, Turkey
Sponsors and Collaborators
Bagcilar Training and Research Hospital
Investigators
Principal Investigator: TANER A. USTA, M.D. Bagcilar Training and Research Hospital,Istanbul,Turkey.

Responsible Party: Bagcilar Training and Research Hospital
ClinicalTrials.gov Identifier: NCT01735331     History of Changes
Other Study ID Numbers: BEHGynObs-3
First Posted: November 28, 2012    Key Record Dates
Last Update Posted: August 7, 2015
Last Verified: August 2015

Keywords provided by Bagcilar Training and Research Hospital:
Vascular endothelial growth factor, Recurrent Pregnancy Loss

Additional relevant MeSH terms:
Abortion, Spontaneous
Fetal Death
Abortion, Habitual
Pregnancy Complications
Death
Pathologic Processes
Mitogens
Endothelial Growth Factors
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Growth Substances
Physiological Effects of Drugs